TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06236568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-HOPE machine perfusion
Description: use of the device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Liver transplantation for HCC within Milan criteria

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver transplantation
Description: Liver transplantation for HCC within Milan criteria
Study: NCT05692635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
Study: NCT05393063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK127
Description: Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
Study: NCT04588688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
Study: NCT05555394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercise
Description: It consists in stretching movements of whole body
Study: NCT05692635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given intravenously
Study: NCT04605016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrophilic surface implants
Description: A dental implant with hydrophilic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrophobic surface implants
Description: A dental implant with hydrophobic surface will be placed and restored in single-tooh gaps of the posterior region of the mandible or maxilla.
Study: NCT05171582

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 1 (Test group)
Description: After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 2 (Control group)
Description: After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
Study: NCT04949178

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study.
Study: NCT04736108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg orally daily for 24 weeks before radical prostatectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 5 mg oral low dose prednisone, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 10.8 mg goserelin hypodermic once per 12 weeks
Study: NCT06296524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Footcore exercises and conventional therapy
Description: 30 minutes exercises protocol will be provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy will be provided.
Study: NCT04776265

Intervention type: OTHER
Intervention: Evaluation of therapeutical approach after ASCT
Description: Evaluation of therapeutical approach after ASCT
Study: NCT05172752

Intervention type: OTHER
Group type: OTHER
Intervention: Citizen Scientist Training Program
Description: Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.

Intervention type: OTHER
Group type: OTHER
Intervention: Stakeholder Consultation Core Program
Description: Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
Study: NCT06457178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-Based Intervention for Oncology Patients
Description: An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for Oncology Patients
Description: A program was prepared to support oncology patients in physical and psychological symptom management.
Study: NCT05033938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Mobilization Protocol
Description: Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Mobilization Protocol
Description: Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
Study: NCT04822376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ansuvimab
Description: Human monoclonal antibody to Zaire strain GP (EBOV GP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ansuvimab
Description: Human monoclonal antibody to Zaire strain GP (EBOV GP)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ervebo
Description: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
Study: NCT06575413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Electrical Stimulation
Description: The patients underwent SEEG with at least one electrode targeting the claustrum. The investigators used the claustrum as a target for both mapping and CCEP, recording changes in cortical electrical activity.
Study: NCT05516927

Intervention type: DIAGNOSTIC_TEST
Intervention: Freenome Test
Description: Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.

Intervention type: DIAGNOSTIC_TEST
Intervention: Freenome Test
Description: Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
Study: NCT05430880

Intervention type: DIAGNOSTIC_TEST
Intervention: impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)
Description: Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli
Study: NCT06555991

Intervention type: OTHER
Group type: OTHER
Intervention: SIRSI and TSK-SI
Description: The SIRSI and TSK-SI as well as the WOSI and RTS-, Clinical- and Demographic Information are gathered. The SIRSI and TSK-SI are re-administered one week later
Study: NCT06284447

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non interventional study
Study: NCT05946902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine
Description: tolterodine 4 mg per day
Study: NCT06354140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year
Study: NCT04759066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEALiX
Description: HEALiX is a non-restraint patient safety device
Study: NCT05684094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension and advance
Description: Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular sleep duration and timing
Description: Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
Study: NCT05362110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803-3
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2002
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2003-3
Description: Placebo drug. Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2004
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT05876013

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Randomized between hamstring and patellar tendon graft

Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Randomized between hamstring and patellar tendon graft
Study: NCT06375668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
Study: NCT05421364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)
Description: Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
Study: NCT04928703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV administration
Study: NCT06643507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: regenerative properties

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALB-PRF
Description: regenerative properties
Study: NCT05200832

Intervention type: OTHER
Intervention: Online questionnaire
Description: Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.

Intervention type: OTHER
Intervention: Online questionnaire
Description: Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.

Intervention type: OTHER
Intervention: Semi-structured interview
Description: 20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.

Intervention type: OTHER
Intervention: Semi-structured interview
Description: 20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
Study: NCT04574011

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive leg raising
Description: Raise the patient's lower limb at a 45 degree angle while lying down

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive leg raising
Description: Raise the patient's lower limb at a 45 degree angle while lying down
Study: NCT06044454

Intervention type: OTHER
Intervention: qXR
Description: a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
Study: NCT06246175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 injection
Study: NCT06192277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Patients are screened to confirm they are low risk for a penicillin allergy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Penicillin
Description: Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose Penicillin
Description: Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remove allergy label
Description: Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
Study: NCT04972292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of codeine 30 mg/dipyrone 500 mg
Description: Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylex
Description: Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Study: NCT05001256

Intervention type: OTHER
Intervention: questionnaire study
Description: Participants will be surveyed through face-to-face interviews.
Study: NCT06162858

Intervention type: OTHER
Group type: OTHER
Intervention: IMU (Inertial Measurement Devices)
Description: Functional placing and reaching of objects of different weights on different heights

Intervention type: OTHER
Group type: OTHER
Intervention: IMU (Inertial Measurement Devices)
Description: Functional placing and reaching of objects of different weights on different heights
Study: NCT06034665

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
Study: NCT06668597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational educational program to improve sleep quality in OSA patients through adherence to CPAP
Description: Phase 1 (Pre-adaptation Psychoeducation): The participant will be shown, within two days prior to the home visit by the provider, which usually takes place within three days of the visit with the pulmonologist, the necessary materials (device, masks, and tubing), along with an educational video on the topic of OSA (duration 25 minutes); Phase 2 (Motivational Interview): Following the first night of titration and use of the CPAP, the participant will be contacted by phone for a brief motivational interview (duration 25 minutes); Phase 3 (Psychological Support Interview): One week after the provider's intervention and the start of the CPAP adaptation period, the participant will be contacted again for a support interview regarding the adaptation process to CPAP (duration 40 minutes). The first week of adaptation is considered a high-risk period for abandonment of device use; Phase 4 (Monitoring Interview): Two weeks after the provider's intervention and the start o
Study: NCT04371952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: comparison of doxycycline 200 mg/day to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo : lactose, 380 mg/gélule
Study: NCT06357754

Intervention type: BIOLOGICAL
Intervention: Idecabtagene vicleucel
Description: As per product label

Intervention type: BIOLOGICAL
Intervention: Lisocabtagene maraleucel
Description: As per product label
Study: NCT06671717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
Description: Drug: Pralatrexate, Chidamide~1. Pralatrexate: 30 mg/m2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment)~2. After the 6-week therapy, the patients should receive PET/CT evaluation.~3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week.~4. After the second cycle of 6-week therapy, the patients should receive PET/CT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies.
Study: NCT06673316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Design thinking workshop
Description: The workshop will cover the five stages of design thinking, allowing students to apply these principles to real-world healthcare challenges in their future practice.